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ImmunoprophylaxisA B S T R A C T
Bacillus Calmette–Gue´rin (BCG) remains the only widely used vaccine against tuberculosis
(TB). Consistent efficacy has been proved in infants but not in adults from developing
countries. Epidemiological and experimental studies have pointed out that, prior exposure
to prevailing environmental mycobacteria could be responsible for the poor efficacy of BCG
as an anti-TB vaccine in adults living in developing countries. Sensitization by environmen-
tal mycobacteria may down-modulate the immunologic behavior of BCG on the one hand
and may mask its efficacy on the other hand. Some of the important deciding factors for
poor efficacy of BCG, due to exposure of the subjects to prevailing environmental mycobac-
teria, are thought to be (i) Life stage: neonatus versus adolescence; (ii) shared antigens
between prevailing environmental mycobacteria and BCG; and (iii) generation of cross-
reactive T-regulatory cells against environmental mycobacteria and BCG. In this communi-
cation, some novel strategies have been discussed for countering the down modulating
impact of environmental mycobacteria towards performance of BCG as an anti-TB vaccine.
 2014 Asian-African Society for Mycobacteriology. Published by Elsevier Ltd. All rights
reserved.Introduction
Tuberculosis (TB) caused by Mycobacterium tuberculosis is a ma-
jor global health problem, causing more than 1.3 million
deaths every year [1]. The most effective and economic way
of controlling this problem would be the availability of an
effective vaccine. Bacillus Calmette–Gue´rin, known as BCG
in the abbreviated form, is an attenuated form of Mycobacte-
rium bovis which was isolated by Albert Calmette and Camille
Gue´rin nearly a century ago and highly resembles M. tubercu-
losis [2]. The use of BCG for human vaccination against TB was
initiated in 1921 and to date there is no alternate of this vac-
cine. Immunologically, BCG is known to generate T-cell helper
type-1 (Th1) immunity for protection of the host from M.
tuberculosis infection [3]. As documented, BCG has been found
to be significantly protective against severe forms (dissemi-
nating and meningeal) of TB in children; however, its efficacy
in adults is inconsistent and varies from 0–80% in different
geographical regions [3,4]. Moreover, there are evidences of
exacerbated disease in certain vaccinated individuals. Never-
theless, BCG is still being used worldwide for vaccinationagainst TB despite foregoing drawbacks. The poor perfor-
mance of BCG in developing countries, where rates of TB
are much higher, is very discouraging. The reasons why BCG
is not very effective in immunocompetent individuals are
considered to be: strain differences in BCG, prevalence of
environmental mycobacteria, genetics of host, nutritional
factors and presence of helminthes co-infections, etc. [5].
Among the various reasons for poor efficacy of BCG in immu-
nocompetent individuals, prior exposure to environmental
mycobacteria is thought to be an important and widely ac-
cepted cause of poor efficacy of BCG vaccine in adults from
developing countries [3,6–10]. This study discusses how the
environmental mycobacteria may contribute towards yielding
weak efficacy of BCG as an anti-TB vaccine. Also, this study
describes possible strategies to overcome such down-modu-
lating impacts towards performance of BCG as a vaccine.
BCG and its efficacy in neonates versus adults
BCG has been reported to be significantly effective in children
when it is delivered in the neonatal stage at birth and the
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vaccination [3]. It is well-documented that in addition to
immunizing the Th1 cells, BCG is known to act as an immu-
nomodulator [11–13] as well. Though BCG primarily induces
Th1-type of immune response [3], depending upon antigen
and cytokine milieu, BCG may also induce Th2-like immune
response [14,15]. At the neonatal stage, the immune system
is considered to be immature, and along with aging, progres-
sive maturation of the immune system occurs due to
persistent exposure to antigens present in the surroundings
[16–18]. In neonates, the naı¨ve Th0 cells are abundant [19]
and along with maturation of the immune system, these cells
switch towards Th1 or Th2. Since exposure of the immune
system to environmental mycobacteria is expected to be less
in neonates when compared with adults, down-modulation
of the BCG efficacy by environmental mycobacteria would
be lower at the neonatal stage. Hence, during the develop-
mental stage of the immune system in the neonates,
exposure to vaccinated BCG may play a pivotal role in switch-
ing the naı¨ve Th cell towards Th1. On the other hand, adults
have a mature immune system and almost an established
Th1/Th2 profile. When compared with adults, the better
efficacy [20] of BCG in infants/children might be due to more
intense switching of the immune system towards Th1 dur-
ing the neonatal stage. This all could be due to immunomod-
ulating as well as immunizing behavior of BCG at the level of
Th1.
Regarding adults, the efficacy of BCG has been reported to
be lower in the developing countries [3] where most of the
people from the neonatal stage onwards live in an environ-
ment where mycobacteria are highly prevalent. Hence, along
with aging as well as persistent exposure to mycobacteria, a
consistent evocation of the Th1-mediated immunity occurs.
Of course, the total period of exposure of the adults to envi-
ronmental mycobacteria remains more than the time span
needed for growth of a neonate to a child. During such a time
span of about 15 years for reaching the neonate to adoles-
cence stage, the immune response involving shift (due to
environmental mycobacteria) of Th0/Th2 to Th1 might reach
a threshold where subsequent vaccination with BCG may not
show a significant difference in protection between the non-
vaccinated and vaccinated groups. As a result thereof, it is re-
flected as if efficacy of BCG vaccine is weak or the vaccine is
non-effective. The same has been explained by two hypothe-
ses [3]: (i) blocking hypothesis: due to cell-mediated immunity
generated by exposure of the host to the prevailing environ-
mental mycobacteria, BCG delivered to the host might be
killed. This may result in limiting the available BCG-derived
antigens from further evoking the immune system. Thereby,
a diminished immunity, against M. tuberculosis, in the host
is generated. It is called blocking effect of environmental
mycobacteria towards BCG efficacy; and (ii) masking hypoth-
esis: it is a phenomenon where the background immunity
generated due to prior exposure of individuals to environ-
mental mycobacteria masks the efficacy of subsequent
BCG vaccination. As a result thereof, it is reflected as if
efficacy of the BCG vaccine is weak or the vaccine is non-
effective.Possible role of T-regulatory cells on efficacy of
BCG
T-regulatory (Treg) cells [21] are subtypes of CD4+ T-helper
cells that are known to regulate the immune system by sup-
pressing the proliferation of lymphocytes, the production of
cytokines and the production of antibodies. Primarily, there
are two subsets of regulatory cells: (i) adaptive – such Treg
cells are induced in the periphery due to stimulation by pre-
vailing sub-optimal levels of antigens; and (ii) natural – these
are derived from thymus and already have immune-sup-
pressing capability. Induced Treg cells are again of two types:
(i) iTr cells which have suppressive action by releasing IL-10;
and (ii) Th3 cells which act by releasing TGF-b, an immuno-
suppressive cytokine. Treg cells also act through cell–cell
contact where CTLA-4 (cytotoxic lymphocyte associated anti-
gen-4) present on Treg cells modulates functions of
antigen-presenting dendritic cells, through binding to CD80
and/or CD86 molecules on antigen presenting cells. This re-
sults in inhibition of maturation, down-regulation of CD80/
CD86, and induction of immunoregulatory enzyme indole-
amine-2,3-desoxygenase which transmits an inhibitory signal
to T-cells. Also, Treg cells compete with effector CD4+ T-cells for
interaction with antigen-captured antigen-presenting cells [22].
Currently, the vaccine immunogenicities are analyzed
keeping possible involvement of Treg cells towards dampen-
ing of their efficacies. In the context of the anti-TB vaccine,
the environmental mycobacteria are considered to weaken
the efficacy of BCG. There is information describing the induc-
tion of Treg cells by environmental mycobacteria [8,23,24]. The
sensitised Treg cells generated by such antigens are thought to
be stimulated by vaccinated BCG which in turn may dampen
the immune response generated by BCG through inhibiting
the T-cell effector functions [8]. Additionally, BCG itself has
also been reported to be involved in the generation of Treg
cells [25–27]. Priming the host with BCG vaccine followed by
boosting with Treg down-regulating mycobacterial proteins
has been reported to be promising [28,29]. This further sup-
ports implication of Treg cells in down-modulating the effi-
cacy of BCG as a vaccine. However, attenuation of Treg
concomitant to immunization with BCG and before immuni-
zation with BCG did not improve the vaccine outcome
[25,30]. These findings also point out that Treg cells generated
after BCG vaccination may play a role in suppressing the anti-
TB efficacy of BCG vaccine. Treg cells are known to be pro-
duced during M. tuberculosis infection as well [31,32], which
may play an important role in TB pathogenesis [33–38] and
also in further dampening the BCG immunizing capacity
[30,39] against TB. Thus, the Treg cells have suppression effect
on the efficacy of BCG at three different levels described in the
foregoing. It is speculated that pre-exposure to mycobacterial
antigens (present in environmental mycobacteria) may induce
and sensitize the Treg cells in the host. These sensitized cells
may further be stimulated by vaccination with BCG and subse-
quently by M. tuberculosis infection. Eventually, all this may re-
sult in the generation of a larger pool of Treg cells which in
turn could influence the BCG vaccine efficacy [24]. Keeping
all of this information in view, it is worth mentioning that
Fig. 1 – Strategies for avoiding the impact of environmental
mycobacteria (EM) on efficacy of BCG as a vaccine against
tuberculosis.
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may initiate the process leading towards down-modulation
of the efficacy of the BCG vaccine.
Perspectives
The foregoing discussion points out that, probably, shared
antigens between environmental mycobacteria and BCG
may be responsible for blocking as well as masking the effect
towards immunizing the efficiency of the anti-TB vaccine.
Such effects due to environmental mycobacteria may not oc-
cur only with conventional BCG; rather, they may be noticed
even with genetically engineered BCG as well. This study sug-
gests two remedies (Fig. 1) that may help in unravelling the
factual efficacy of BCG vaccines and in improving the perfor-
mance of anti-TB vaccines respectively: (i) the testing of can-
didate BCG vaccines must be conducted with the people living
in the regions where prevalence of environmental mycobacte-
ria may be negligible. Doing so would eliminate the blocking
and masking effects of environmental mycobacteria; and (ii)
genes encoding only those proteins that may be present in
BCG as well as M. tuberculosis but absent in environmental
mycobacteria may be selected through genomic comparisons
of the concerned mycobacterial species. Employing the se-
lected desirable genes, the corresponding antigens may be
produced by genetic engineering. In case such proteins are
found to be immunologically potential, then they may prove
to be promising antigens for anti-TB vaccines as they would
be devoid of the undesirable down-modulating and masking
effects of environmental mycobacteria.
Keeping in view the possible role of Treg cells towards
weakening the efficacy of the BCG vaccine, this write-up
suggests that (Fig. 1): (i) Strategies to modulate the Treg cell-
mediated down-modulating effect on Th1 cells to weaken
the efficacy BCG need to be developed, perhaps on the lines de-
scribed elsewhere [40]; (ii) Identifying Treg cell-inducing BCGantigens is worth attempting. By identifying immunosuppres-
sive antigens, better BCG vaccines might be created by dissect-
ing out Treg cell-inducing proteins from BCG. Development of
such deficient versions of BCG for Treg cell-inducing proteins
may be carried out by genetic manipulation of BCG genes
through disruption or deletion of concerned genes; And (iii)
Developing recombinant BCG (rBCG) strains expressing Treg
down-regulating antigens might stimulate more potent
immune responses against M. tuberculosis infection.
Most likely, these suggested strategies may lead towards
the bettering of BCG as an anti-TB vaccine. Nonetheless,
whatever may be the strategy to improve the performance
of BCG through reducing the Treg population, the ratio of
Th1-type of CD4 cells (through which BCG acts) and Treg cells
should be maintained at such a level so that tissue damage
might be low with high efficacy of the BCG vaccine.
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